Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-05-17
2005-05-17
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S155100, C424S173100, C424S174100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388800
Reexamination Certificate
active
06893638
ABSTRACT:
The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5116964 (1992-05-01), Capon
patent: 5304635 (1994-04-01), Imam et al.
patent: 5885579 (1999-03-01), Linsley
patent: 6162432 (2000-12-01), Wallner
patent: 0 173 494 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 194 276 (1993-08-01), None
patent: 0 555 880 A2 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 9206193 (1992-04-01), None
patent: WO 9309812 (1993-05-01), None
patent: WO 9428912 (1994-12-01), None
patent: WO 9506481 (1995-03-01), None
patent: WO 9506666 (1995-03-01), None
patent: WO 9819706 (1998-05-01), None
Kandasamy et al. Blood 11 (Par 1): p. 608a (2001).*
Delmer Biotechnology 12:320 (1994).*
Dillman J. Clin Oncol. 12:1497-1515 (1994).*
Falini et al. Lancet 339:1195-1196 (1992).*
Delasie et al. Blood 82:2845-2852 (1993).*
Mundo et al. Blood 83:793-798 (1994).*
Kuchroo et al., “B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy,”Cell, 80:707-718 (1995).
Lenschow et al., “Inhibition of Transplant Rejection Following Treatment with Anti-B7-2 and Anti-B7-1 Antibodies,”Transplantation60:1171-1178 (1995).
Lenschow et al. “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse,”J. Exp. Med. 181:1146-1155 (1995).
Nakajima et al., “Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule,”Euro. J. Immunol. 25(11):3060-3069 (Nov. 1995).
Van Gool et al., “Synergy Between Cyclosporin A and a Monoclonal Antibody to B7 in Blocking Alloantigen-Induced T-Cell Activation,”Blood, 83:176-183 (1994).
Wettendorf et al., “Generation of Humanized Fab Fragments of B7-24 mAb, An Antibody with Potential Use in the Prevention of Graft Rejection and Development of Graft-Versus-Host Disease,”Med. Fac. Landbouww. Univ. Gent. 60(4):2057-2063, Published Sep. 27, 1995—not early enough to be valid prior art.
Armitage, R.J., et al., Molecular and biologial characterization of a murine ligand for CD40, Nature, 1992, 357:80-82.
Asuma, M. et al., Functional Expression of B7/BB1 on Activated T Lymphocytes, J. Exp. Med., 1992, 177:845-850.
Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol., 1981, 11:195-199.
Blazar, B.R. et al., Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells, J Immunol., 1996, 157:3250-3259.
Capon, D.J., et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, 1989, 337, 525-531.
Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett., 1985, 188(1):33-36.
Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 1994, 145(3), 200-205 & 244-249.
Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the lignad for CD40, Science, 1993, 261:1328-1330.
Freeman, G.J. et al., Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice, Science, 1993, 262:907-909.
Freeman, G.J. et al., B7, A new member of the Ig Superfamily with unique expression on activated and neoplastic B cells, J of Immunol., 1989, 143:2714-2722.
Freeman, G.J. et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science, 1993, 262:909-911.
Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
Gottlieb, A, et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol., 2000, 114:840, Abstract No. 546.
Gottlieb, A. et al., Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody, J Am Acad Dermatol., 2002, 47:692-700.
Guinan, E.C. et al., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood. 1994, 84:3261-3282.
Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 1991, 636:251-265.
Hariharan et al., “In vitro and in vivo studies demonstating the effectiveness of IDEC-114 and rituximab (Rituxan®) in therapy of B-cell lymphoma in experimental models; Confidential Report (laboratory notebook and data binder 2552, 2646, 2665, and 2671),” Jun. 29, 2001.
Hathcock, K.S. et al., Identification of an alternative CTLA-4 ligand costimulatory for T cell activation, Science, 1993, 262:905-907.
Hollenbaugh, D., et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, The EMBO J., 1992, 11(12):4313-4321.
Janeway, C.A. et al., Signals and Signs for Lymphocyte Responses, 1994, 76:275-285.
Kahan, B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
Karpus, W.J., et al., CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis, J. Immunol., 1989, 143:3492-3497.
Laman, J., et al., The role of gp39 (CD40 ligand) in EAE and MS, Journal of Neuroimmunology, 1994, 54(1-2):175.
Lederman, S., et al., Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), J. Exp. Med., 1992, 175:1091-1101.
Lider, O., et al., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. J. Immunol., 1989, 142:748-752.
Linsley, P.S. et al., The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol., 1993, 11:191-212.
Linsley, P.S. et al., T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1, Proc. Natl. Acad., 1990, 87:5031-5035.
McCafferty, J., et al., Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 1990, 348:552-554.
Miller, A., et al., Antigen-driven bystander suppression after oral administration of antigens, J. Exp. Med., 1991, 174:791-798.
Mokhtarion, F., et al., Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice, Nature, 1984, 309:356-358.
Morrison, S., et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad, Sci. U.S.A., 1985, 81:6851-6855.
Nickoloff, B.J. et al., T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28, Blood, 1994, 83:2580-2586.
Noelle, R.J., et al., A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells, Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
Olsson, L., et al., Human-human monoclonal antibody-producing hybridomas: technical aspects, Meth, Enzymol., 1982, 92:3-17.
Perrin, P.J. et al., Opposing effects of CTLA4-lg and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis, J Neuroimmunol., 1996, 65:31-39.
Pesoa, S.A., et al., Regulation of experimental allergic encephalomyelitis, Part 5, Role of the recipient in suppressor cell induction, J. Neuroimmunol, 1984, 7:131-135.
Pettinelli, C.B., et al., Adoptive transfer of experimental allergic encephalomyelitis in
Anderson Darrell R.
Brams Peter
Hanna Nabil
Heard Cheryl
Shestowsky William S.
Gambel Phillip
Pillsbury & Winthrop LLP
LandOfFree
Methods for treating b cell lymphoma using CD80-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating b cell lymphoma using CD80-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating b cell lymphoma using CD80-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370801